Search results for "Nadroparin calcium"

showing 2 items of 2 documents

Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins.

2006

The aim of this study was to evaluate different durations of treatment in patients with calf venous thrombosis (CVT) involving 1 or more deep veins. The authors studied 2 groups of patients with postsurgical CVT diagnosed by echo-color Doppler. The first group consisted of 68 patients with CVT involving a single vein, and the second group consisted of 124 patients with CVT involving 2 or more veins. Immediately after diagnosis, all patients were treated with nadroparin calcium and sodium warfarin. Heparin treatment was withdrawn after 5–6 days of treatment, when the international normalized ratio (INR) was stabilized between 2 and 3. Each group was divided into 2 subgroups receiving antico…

AdultMalemedicine.medical_specialtyFemoral vein030204 cardiovascular system & hematologyDrug Administration ScheduleLesion03 medical and health sciences0302 clinical medicinePostoperative ComplicationsMedicineHumans030212 general & internal medicineThrombusUltrasonography Doppler ColorVeinAgedVenous ThrombosisLegbusiness.industryAnticoagulantsNadroparinHeparinMiddle Agedmedicine.diseaseNadroparin calciumSurgeryVenous thrombosismedicine.anatomical_structureAnesthesiacardiovascular systemFemaleWarfarinmedicine.symptomCardiology and Cardiovascular MedicinebusinessSurgical patientsmedicine.drugAngiology
researchProduct

The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein …

2013

The objective of this study was to evaluate whether the presence of a plasminogen activator inhibitor type 1 (PAI-1) promoter polymorphism 4G/5G could significantly influence the proximal extension of vein thrombosis in spite of anticoagulant treatment in patients with calf vein thrombosis (CVT) following orthopaedic, urological and abdominal surgery. We studied 168 patients with CVT, who had undergone orthopaedic, urological and abdominal surgery, subdivided as follows: first, 50 patients with thrombosis progression; second, 118 patients without thrombosis progression. The 4G/5G polymorphism of the plasminogen activator inhibitor 1 was evaluated in all patients and in 70 healthy matched co…

Malemedicine.medical_specialtymedicine.medical_treatmentGastroenterologychemistry.chemical_compoundPostoperative ComplicationsGene FrequencyRisk FactorsInternal medicineFibrinolysisPlasminogen Activator Inhibitor 1Factor V LeidenmedicineOdds RatioHumansGenetic Predisposition to Disease4G/5G genotype PAI-1 thrombotic lesionsPromoter Regions GeneticAllelesAgedVenous ThrombosisPolymorphism Geneticbusiness.industryHematologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseNadroparin calciumThrombosisSurgerychemistryPlasminogen activator inhibitor-1Case-Control StudiesFemalebusinessPlasminogen activatorAbdominal surgerymedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct